Display options
Cite
Adams WK, Halberstadt AL, van den Buuse M. Hippocampal serotonin depletion unmasks differences in the hyperlocomotor effects of phencyclidine and MK-801: quantitative versus qualitative analyses. Front Pharmacol. 2013;4:109doi: 10.3389/fphar.2013.00109.
Adams, W. K., Halberstadt, A. L., & van den Buuse, M. (2013). Hippocampal serotonin depletion unmasks differences in the hyperlocomotor effects of phencyclidine and MK-801: quantitative versus qualitative analyses. Frontiers in pharmacology, 4109. https://doi.org/10.3389/fphar.2013.00109
Adams, Wendy K, et al. "Hippocampal serotonin depletion unmasks differences in the hyperlocomotor effects of phencyclidine and MK-801: quantitative versus qualitative analyses." Frontiers in pharmacology vol. 4 (2013): 109. doi: https://doi.org/10.3389/fphar.2013.00109
Adams WK, Halberstadt AL, van den Buuse M. Hippocampal serotonin depletion unmasks differences in the hyperlocomotor effects of phencyclidine and MK-801: quantitative versus qualitative analyses. Front Pharmacol. 2013 Aug 29;4:109. doi: 10.3389/fphar.2013.00109. eCollection 2013. PMID: 24009584; PMCID: PMC3756227.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2013 Aug 29;4:109. doi: 10.3389/fphar.2013.00109. eCollection 2013.

Hippocampal serotonin depletion unmasks differences in the hyperlocomotor effects of phencyclidine and MK-801: quantitative versus qualitative analyses.

Frontiers in pharmacology

Wendy K Adams, Adam L Halberstadt, Maarten van den Buuse

Affiliations

  1. Behavioural Neuroscience Laboratory, Florey Institute for Neuroscience and Mental Health, University of Melbourne Melbourne, VIC, Australia ; Centre for Neuroscience, University of Melbourne Melbourne, VIC, Australia.

PMID: 24009584 PMCID: PMC3756227 DOI: 10.3389/fphar.2013.00109

Abstract

Antagonism of N-methyl-D-aspartate (NMDA) receptors by phencyclidine (PCP) is thought to underlie its ability to induce a schizophrenia-like syndrome in humans, yet evidence indicates it has a broader pharmacological profile. Our previous lesion studies highlighted a role for serotonergic projections from the median, but not dorsal, raphe nucleus in mediating the hyperlocomotor effects of PCP, without changing the action of the more selective NMDA receptor antagonist, MK-801. Here we compared locomotor responses to PCP and MK-801 in rats that were administered 5,7-dihydroxytryptamine (5,7-DHT) into either the dorsal or ventral hippocampus, which are preferentially innervated by median and dorsal raphe, respectively. Dorsal hippocampus lesions potentiated PCP-induced hyperlocomotion (0.5, 2.5 mg/kg), but not the effect of MK-801 (0.1 mg/kg). Ventral hippocampus lesions did not alter the hyperlocomotion elicited by either compound. Given that PCP and MK-801 may induce different spatiotemporal patterns of locomotor behavior, together with the known role of the dorsal hippocampus in spatial processing, we also assessed whether the 5,7-DHT-lesions caused any qualitative differences in locomotor responses. Treatment with PCP or MK-801 increased the smoothness of the path traveled (reduced spatial d) and decreased the predictability of locomotor patterns within the chambers (increased entropy). 5,7-DHT-lesions of the dorsal hippocampus did not alter the effects of PCP on spatial d or entropy - despite potentiating total distance moved - but caused a slight reduction in levels of MK-801-induced entropy. Taken together, serotonergic lesions targeting the dorsal hippocampus unmask a functional differentiation of the hyperlocomotor effects of PCP and MK-801. These findings have implications for studies utilizing NMDA receptor antagonists in modeling glutamatergic dysfunction in schizophrenia.

Keywords: 5,7-dihydroxytryptamine; MK-801; entropy; hippocampus; locomotor hyperactivity; phencyclidine; serotonin; spatial d

References

  1. Eur J Pharmacol. 2006 Jul 1;540(1-3):53-6 - PubMed
  2. Behav Brain Res. 2009 Dec 7;204(2):410-5 - PubMed
  3. Neurosci Lett. 1996 May 17;209(3):153-6 - PubMed
  4. Eur J Pharmacol. 1988 Jan 12;145(2):223-6 - PubMed
  5. Eur J Pharmacol. 1995 Jul 4;280(2):R9-11 - PubMed
  6. Brain Res Brain Res Rev. 2000 Mar;31(2-3):302-12 - PubMed
  7. Neurosci Res. 2001 May;40(1):97-103 - PubMed
  8. J Pharmacol Exp Ther. 1999 Sep;290(3):1292-8 - PubMed
  9. Neuropsychopharmacology. 2000 Sep;23(3):223-39 - PubMed
  10. Psychopharmacology (Berl). 2003 Nov;170(3):309-319 - PubMed
  11. Brain Res. 1981 Feb 23;207(1):95-107 - PubMed
  12. Cell Mol Life Sci. 2007 Feb;64(4):401-31 - PubMed
  13. Psychopharmacology (Berl). 2009 Aug;205(2):203-16 - PubMed
  14. Pharmacopsychiatry. 1998 Jul;31 Suppl 2:104-9 - PubMed
  15. Mol Psychiatry. 2005 Sep;10(9):877-83 - PubMed
  16. Behav Brain Res. 2005 Apr 15;159(1):95-103 - PubMed
  17. Biochem Pharmacol. 1988 Sep 1;37(17):3277-83 - PubMed
  18. Neuropharmacology. 2007 Mar;52(3):949-57 - PubMed
  19. Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84 - PubMed
  20. Behav Brain Res. 1981 Nov;3(3):341-59 - PubMed
  21. Neurochem Res. 2007 Apr-May;32(4-5):535-53 - PubMed
  22. Int J Neuropsychopharmacol. 2000 Dec;3(4):333-338 - PubMed
  23. Neuroreport. 1998 Sep 14;9(13):2985-8 - PubMed
  24. Eur J Pharmacol. 1989 Aug 11;167(1):127-35 - PubMed
  25. Nat Rev Neurosci. 2004 May;5(5):361-72 - PubMed
  26. Neuropharmacology. 2000 Sep;39(12):2318-28 - PubMed
  27. Behav Brain Res. 1993 Feb 26;53(1-2):11-20 - PubMed
  28. Psychopharmacology (Berl). 2004 Jun;174(1):99-110 - PubMed
  29. Br J Psychiatry. 2006 Dec;189:565-6 - PubMed
  30. Synapse. 2005 Dec 15;58(4):275-7 - PubMed
  31. Neuropsychopharmacology. 2009 Jul;34(8):1958-67 - PubMed
  32. Neuropharmacology. 2008 Nov;55(6):1048-55 - PubMed
  33. Brain Res. 1971 Nov;34(1):171-5 - PubMed
  34. Psychopharmacology (Berl). 2011 Feb;213(2-3):289-305 - PubMed
  35. J Neural Transm (Vienna). 1996;103(1-2):131-46 - PubMed
  36. AMA Arch Neurol Psychiatry. 1959 Mar;81(3):363-9 - PubMed
  37. Eur J Pharmacol. 1989 Aug 3;166(3):359-66 - PubMed
  38. Neuropsychopharmacology. 1994 Nov;11(3):167-77 - PubMed
  39. Trends Pharmacol Sci. 1990 Feb;11(2):81-6 - PubMed
  40. Eur J Neurosci. 1999 Dec;11(12):4419-32 - PubMed
  41. Clin Neuropharmacol. 1995 Jun;18(3):237-49 - PubMed
  42. Neuropsychopharmacology. 1999 Mar;20(3):201-25 - PubMed
  43. Neuropsychopharmacology. 2003 Sep;28(9):1622-32 - PubMed
  44. J Psychiatr Res. 1999 Nov-Dec;33(6):523-33 - PubMed
  45. Psychopharmacology (Berl). 2004 Nov;176(3-4):287-95 - PubMed
  46. Pharmacol Biochem Behav. 1994 May;48(1):111-8 - PubMed
  47. Neuropharmacology. 1991 Jun;30(6):629-36 - PubMed
  48. Brain Res. 2005 Jul 12;1049(2):217-26 - PubMed
  49. Neuropharmacology. 1995 Dec;34(12):1597-606 - PubMed
  50. Res Commun Chem Pathol Pharmacol. 1991 Aug;73(2):181-95 - PubMed
  51. Eur J Pharmacol. 1998 Feb 19;343(2-3):135-43 - PubMed
  52. Psychopharmacology (Berl). 1991;104(1):6-16 - PubMed
  53. Anesthesiology. 1998 Mar;88(3):768-74 - PubMed
  54. Rev Neurosci. 2007;18(3-4):253-81 - PubMed
  55. Neuropharmacology. 2011 Sep;61(3):458-67 - PubMed
  56. Rev Neurosci. 2002;13(2):183-94 - PubMed
  57. Mol Psychiatry. 2004 Nov;9(11):984-97, 979 - PubMed
  58. J Neural Transm (Vienna). 1998;105(4-5):365-96 - PubMed
  59. Eur J Neurosci. 2004 Dec;20(12):3424-32 - PubMed
  60. Neurosci Lett. 2007 Mar 30;415(3):274-8 - PubMed
  61. Brain Res. 2000 Jun 30;869(1-2):194-202 - PubMed
  62. Neurotoxicol Teratol. 1994 Jul-Aug;16(4):343-53 - PubMed
  63. Ann N Y Acad Sci. 2003 Nov;1003:131-7 - PubMed
  64. Mol Psychiatry. 2002;7(8):837-44 - PubMed
  65. Trends Neurosci. 1990 Jul;13(7):290-6 - PubMed
  66. Arch Gen Psychiatry. 1994 Mar;51(3):199-214 - PubMed
  67. Psychopharmacology (Berl). 2009 Nov;206(4):665-76 - PubMed
  68. Br J Pharmacol. 1983 Jun;79(2):565-75 - PubMed
  69. Neuropsychopharmacology. 2003 Dec;28(12):2138-47 - PubMed
  70. Eur J Pharmacol. 2004 Mar 19;488(1-3):1-9 - PubMed
  71. Hippocampus. 1998;8(6):608-19 - PubMed
  72. Curr Opin Pharmacol. 2005 Feb;5(1):101-6 - PubMed
  73. Brain Res Brain Res Rev. 2000 Mar;31(2-3):320-9 - PubMed

Publication Types

Grant support